ADDRESS II Phase 2b trial

April 18, 2018April 18, 2018

Atacicept Reduces Disease Burden in Lupus Patients with High Disease Activity, Study Shows

News

Treatment with 150 mg atacicept significantly improves outcomes in systemic lupus erythematosus (SLE) patients with high disease activity, data from a Phase 2b clinical trial show. The results of ... Read more

April 9, 2018April 10, 2018

Atacicept, a B-cell Targeting Protein, Reduced Lupus Flares in Clinical Trials

News

Treatment with atacicept — a protein that targets the immune system — significantly reduced disease flares in patients with systemic lupus erythematosus (SLE), data from EMD Serono‘s Phase 2 ... Read more

November 13, 2017November 13, 2017

Lupus Patients with High Disease Activity Show ‘Significant Improvement’ After Taking Atacicept

News

EMD Serono‘s atacicept can effectively reduce disease activity among lupus patients with high disease activity at baseline, according to new data from the Phase 2b ADDRESS II trial. The ... Read more

November 6, 2017

Atacicept Found to Be Safe, with Early Indications of Effectiveness in Lupus Patients

News

Results from a 24-week Phase 2b study show that atacicept treatment is safe and reduces disease activity and severe flare in systemic lupus erythematosus (SLE) patients, particularly in those ... Read more

Pin It on Pinterest